Nirmatrelvir not checked
Pfizer · PF-07321332 · PF-07321332/ritonavir
FollowEvery change as it happens, and a Monday email
Next date
None yet
Trials
4 active
19 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- COVID-19
- Main trialPhase 3
- “The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease.”In the company’s words, NCT05261139 on ClinicalTrials.gov
- Other names
- PF-07321332 · Paxlovid · PF-07321332/ritonavir
Other drugs for COVID-19
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials19
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jul 2026 | EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease | |
| Phase 2/3Completed | 9 Dec 2021 | EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 | |
| Phase 2/3Completed | 12 Apr 2022 | A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection | |
| Phase 2/3Terminated | 25 Jul 2022 | Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). | |
| Phase 2Completed | 17 Jul 2023 | A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System | |
| Phase 2Withdrawn | 21 Sep 2023 | A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19 | |
| Phase 2Completed | 27 Sep 2023 | A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir | |
| Phase 1Completed | 1 Sep 2021 | STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS | |
| Phase 1Completed | 9 Oct 2021 | Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir | |
| Phase 1Completed | 7 Dec 2021 | Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332 | |
| Phase 1Withdrawn | 1 Apr 2022 | Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants. | |
| Phase 1Completed | 16 May 2022 | Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation | |
| Phase 1Terminated | 11 Jul 2023 | A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease | |
| Phase 1Completed | 15 Dec 2023 | A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women | |
| Phase 1Terminated | 26 Mar 2025 | A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19 | |
| Phase 2Authorised | not given | OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Study | |
| Phase 3Authorised | not given | Paxlovid long covid-19 prevention trial with recruitment in the community in Norway | |
| Phase 4Ended | not given | TURN-COVID Biobank: The Dutch cohort study tor the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2 | |
| Phase 2Authorised | not given | Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026